Business context and reporting period
This is Park City Group, Inc.’s Form 10-Q for the three months ended September 30, 2022, its fiscal 2023 first quarter. Although the request identifies ReposiTrak, Inc., the filing issuer is Park City Group; the consolidated results include its wholly owned ReposiTrak subsidiary, a SaaS provider of B2B e-commerce, supplier compliance, food safety, and supply-chain solutions.
Financial performance and position
| Metric | Quarter ended Sep. 30, 2022 | Comparable 2021 period | Change |
|---|---|---|---|
| Revenue | $4.720 million | $4.560 million | +4% |
| Operating income | $1.228 million | $1.166 million | +5% |
| Net income | $1.285 million | $0.947 million | +36% |
| Net income applicable to common shareholders | $1.139 million | $0.800 million | +42% |
| Basic and diluted EPS | $0.06 | $0.04 | Up $0.02 |
| Cash provided by operations | $1.811 million | $1.118 million | +62% |
- Operating margin was approximately 26.0%, versus 25.6% a year earlier. Recurring subscription, support, and services revenue rose 6% to $4.678 million and represented nearly all revenue; transaction-based revenue fell to zero from $103,333.
- Cash was $21.628 million at quarter-end. Working capital was $21.276 million, up $0.790 million from June 30, 2022; current assets were $26.372 million and current liabilities $5.096 million.
- Credit-line borrowings were $1.297 million, down from $2.591 million at June 30. The balance sheet also reports $249,145 of notes payable and financing leases, current and long term. Operating lease liabilities totaled approximately $363,000.
- Investing activities used $19,533; financing activities used $1.625 million, including line-of-credit repayments, share repurchases, dividends, and debt/lease payments. Cash increased $166,779 during the quarter.
Changes, outlook, and notable items
- Management attributed revenue growth to recurring subscription and services revenue. Cost of revenue declined 2%, which it linked to eliminating low-margin offerings and cost controls. General and administrative expense rose 12%, driven by insurance, recruitment, benefits, and wage costs; sales and marketing rose 1%.
- Net other income was $117,072 versus net other expense of $180,114 in the prior-year quarter. Management cited an Employee Retention Tax Credit refund gain and higher interest income; the company also recorded a $7,415 unrealized loss on short-term investments. The filing does not quantify the ERTC-related gain separately.
- Management said existing cash and operating cash flow should fund operations, debt obligations, and anticipated quarterly dividends for at least 12 months. No numerical revenue or earnings guidance was provided.
- The $10 million revolving credit facility matures March 31, 2023, bears interest at 1.75% plus one-month LIBOR, and includes liquidity and leverage covenants. The company reported the debt portfolio was entirely variable-rate at quarter-end.
- The board declared a quarterly cash dividend of $0.015 per share, payable on or about November 15, 2022. The company repurchased 20,859 common shares for $103,657 during the quarter.
- Management highlighted the FDA’s November 7, 2022 final rule on FSMA Section 204(d) food traceability. It views the rule as a potential market opportunity for its traceability platform, while noting implementation requirements and timing. The filing says geopolitical conflicts had not materially affected results through the quarter but their future effects were uncertain.
- No material pending or threatened legal proceedings, new risk factors, or material subsequent events were reported. Management considered disclosure controls effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer and reporting scope: the filing is Park City Group, Inc.’s consolidated report, not a standalone ReposiTrak filing.
- Review the credit facility’s March 2023 maturity, LIBOR-based pricing, covenant compliance, and any refinancing or replacement terms.
- Assess the quality and recurrence of the quarter’s earnings improvement, including the amount and accounting of the ERTC refund gain and the effect of investment valuation changes.
- Track whether recurring-revenue growth continues and whether the FSMA traceability rule translates into customer adoption and revenue.
- Reconcile the MD&A’s depreciation and amortization discussion, which states $223,006 for 2022, with the financial statements’ reported $236,006.